Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Endocyte, a biotechnology company, has initiated a randomized Phase II clinical study of the company's investigational drug EC145 in women with platinum-resistant ovarian cancer.
Subscribe to our email newsletter
The Phase II trial, also called the ‘Precedent study’, will evaluate the efficacy and safety of EC145 when administered in combination with pegylated liposomal doxorubicin (PLD).
PLD is widely used as a standard therapy for women with platinum-resistant ovarian cancer. The efficacy and safety of the combination of EC145/PLD will be compared to treatment with PLD without EC145.
In addition to EC145, patients in the Precedent trial will also be treated with a new molecular imaging agent called EC20 developed by Endocyte. By targeting folate receptors, EC20 imaging agent allows clinicians to identify tumors that over-express the folate receptor. Using EC20, doctors may be able to identify, in advance, those patients who will benefit from EC145 therapy.
Richard Messmann, vice president of medical affairs at Endocyte, said: The start of the Precedent study is another important validation of Endocyte’s promising drug guidance system technology platform. This also represents an important milestone in Endocyte’s efforts to develop a range of new drugs and predictive medicine tools to treat cancer and other serious diseases in the years ahead.